Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
基本信息
- 批准号:10626828
- 负责人:
- 金额:$ 60.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdipocytesAdultAgingAutomobile DrivingBiologicalBloodBlood CellsBone MarrowCardiovascular DiseasesCardiovascular systemCellsCessation of lifeChronicChronic Kidney FailureClinicalClonal EvolutionClonal ExpansionCognitiveDNADataDementiaDevelopmentDiseaseDisease ProgressionElderlyEpidemiologyEventFatty acid glycerol estersFemurGenesGeneticGoalsGrowthHematopoiesisHematopoieticHematopoietic stem cellsHumanImpaired cognitionImpairmentIncidenceIndividualInflammatoryInterleukin-6Intervention TrialKidneyKidney DiseasesKnowledgeLinkMagnetic Resonance ImagingMalignant NeoplasmsModelingMutationParticipantPathogenesisPathologicPatient RecruitmentsPatientsPlayPrevalencePrognosisQuality of lifeRenal functionResourcesRisk FactorsRoleShapesSomatic MutationTestingVascular DiseasesVertebral columnWorkage relatedagedblood pressure interventionclinical riskcognitive functioncohortenvironmental stressorfunctional declinegenomic dataglobal healthhigh riskinflammatory markerinsightleukemiametabolomicsmild cognitive impairmentmortalitymutantnovelprospectiverecruitsystemic inflammatory responsetargeted sequencing
项目摘要
PROJECT SUMMARY
Chronic kidney disease (CKD) is a predominantly age-related disorder and is associated with accelerated
cognitive function decline. Despite epidemiological evidence linking mild cognitive impairment (MCI) and
dementia with kidney function decline, we still have an incomplete understanding of the factors involved in their
pathogenesis suggesting that there are other unidentified age-related causal risk factors that drive the
development and progression of MCI, dementia, and kidney function decline. Recent data indicates that aging
humans accumulate leukemia associated somatic mutations in hematopoietic stem cells. These mutations
appear to provide a competitive growth advantage to the mutant cells, allowing progressive clonal expansion
which has been defined as clonal hematopoiesis (CH) and it is characterized by worsening chronic systemic
inflammation. CH is associated with several pathological conditions including cardiovascular disease, however,
its association with cognitive and kidney endpoints has not been explored. In addition, the underlying
mechanisms driving CH remain to be determined. Hence, our primary objective is to establish an association
between CH with MCI, dementia, and kidney disease progression. Given the interplay between CH and aging
related changes in the bone marrow (BM) fat microenvironment, a key secondary goal of this application is to
determine the role of BM fat in the evolution of CH. We will also examine blood metabolite signatures
associated with higher risk for clinically meaningful cognitive and CKD endpoints and higher BM fat content.
Our preliminary data demonstrated a significant occurrence of CH in patients with CKD. Also, we have shown
that BM adipocytes produce a local inflammatory signature including increased interleukin-6 that promotes CH.
These findings provide a strong premise for our hypothesis that CH associates with MCI, dementia and CKD,
and that BM fat plays a significant role in CH development. We will leverage the unique resources of the
Systolic blood Pressure Interventional Trial (SPRINT), including longitudinal data on assessment of cognitive
function and CKD, biospecimens, and DNA enabling assessment of CH. In a subset of 6,000 SPRINT
participants aged 50 or older with normal kidney function at baseline, we will determine CH at baseline using
our targeted sequencing panel and analytic pipeline for somatic mutation calling and assess whether CH
identifies those at highest risk for cognitive and kidney function impairment. We propose 3 aims; Aim 1: To
evaluate the prospective associations between CH and metabolomics with incident MCI and dementia events
among SPRINT participants with normal kidney function at baseline. Aim 2: To evaluate the prospective
associations between CH and metabolomics with kidney disease progression events among SPRINT
participants with normal kidney function at baseline. Aim 3: To define a link between BM fat and clonal
hematopoiesis in CKD. Understanding the disease related risk factors associated with CH and the related
mechanisms may uncover new ways to reduce the burden of MCI, dementia and kidney disease progression.
项目摘要
慢性肾脏病(CKD)是一种主要与年龄相关的疾病,
认知功能下降尽管有流行病学证据表明轻度认知障碍(MCI)和
虽然老年痴呆症伴肾功能下降,但我们对其相关因素仍有不完全的了解,
发病机制表明,还有其他未确定的年龄相关的因果风险因素,驱动
MCI、痴呆和肾功能下降的发展和进展。最近的数据表明,
人类在造血干细胞中积累白血病相关的体细胞突变。这些突变
似乎为突变细胞提供了竞争性生长优势,允许进行性克隆扩增
其被定义为克隆性造血(CH),其特征在于慢性全身性
炎症然而,CH与包括心血管疾病在内的几种病理状况有关,
其与认知和肾脏终点的关联尚未探索。此外,底层
驱动CH的机制仍有待确定。因此,我们的首要目标是建立一个协会,
CH与MCI、痴呆和肾脏疾病进展之间的关系。考虑到CH和衰老之间的相互作用
骨髓(BM)脂肪微环境的相关变化,本申请的关键次要目标是
确定BM脂肪在CH演变中的作用。我们还将检查血液代谢物特征
与具有临床意义的认知和CKD终点的风险较高以及BM脂肪含量较高相关。
我们的初步数据表明,慢性肾病患者中CH的发生率很高。此外,我们还展示了
BM脂肪细胞产生局部炎症信号,包括促进CH的增加的白细胞介素-6。
这些发现为我们的假设提供了强有力的前提,即CH与MCI、痴呆和CKD相关,
并且BM脂肪在CH发展中起重要作用。我们将充分利用
收缩压干预试验(SPRINT),包括认知功能评估的纵向数据
功能和CKD,生物标本和DNA,使CH的评估。在一个子集的6,000 SPRINT
基线时肾功能正常的50岁或以上受试者,我们将使用以下方法确定基线时的CH:
我们的靶向测序面板和分析管道用于体细胞突变调用,并评估CH是否
识别认知和肾功能受损风险最高的人群。我们提出三个目标:目标1:
评估CH和代谢组学与MCI和痴呆事件之间的前瞻性关联
在基线时肾功能正常的SPRINT参与者中。目的2:评估前瞻性
CH和代谢组学与SPRINT中肾脏疾病进展事件之间的相关性
基线时肾功能正常的受试者。目的3:确定BM脂肪和克隆性脂肪之间的联系
CKD中的造血。了解与CH相关的疾病相关危险因素和相关的
这些机制可能会发现减少MCI,痴呆和肾脏疾病进展负担的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michel Benjamin Chonchol其他文献
Michel Benjamin Chonchol的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michel Benjamin Chonchol', 18)}}的其他基金
Clonal hematopoiesis, mild cognitive impairment and kidney function decline
克隆性造血、轻度认知障碍和肾功能下降
- 批准号:
10464393 - 财政年份:2022
- 资助金额:
$ 60.27万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10534531 - 财政年份:2022
- 资助金额:
$ 60.27万 - 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
- 批准号:
10684097 - 财政年份:2022
- 资助金额:
$ 60.27万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10669712 - 财政年份:2021
- 资助金额:
$ 60.27万 - 项目类别:
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease
吸气肌力量训练可降低患有慢性肾病的中年和老年人的收缩压
- 批准号:
10313126 - 财政年份:2021
- 资助金额:
$ 60.27万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
10640074 - 财政年份:2019
- 资助金额:
$ 60.27万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
10400032 - 财政年份:2019
- 资助金额:
$ 60.27万 - 项目类别:
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.
补充烟酰胺核苷可治疗中度至重度 CKD 患者的动脉僵硬度和收缩压升高。
- 批准号:
9762288 - 财政年份:2019
- 资助金额:
$ 60.27万 - 项目类别:
相似国自然基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
- 批准号:81970721
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
- 批准号:
23K16058 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
- 批准号:
23K10969 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
- 批准号:
10751284 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
- 批准号:
23K19518 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
- 批准号:
23K18303 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
- 批准号:
23H03065 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
- 批准号:
23K05107 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
- 批准号:
10655793 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
- 批准号:
23K05594 - 财政年份:2023
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NKT cell activation depend on lipid accumulation in adipocytes
NKT 细胞的激活取决于脂肪细胞中的脂质积累
- 批准号:
22K08679 - 财政年份:2022
- 资助金额:
$ 60.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)